Product: Pim-1 Antibody
Catalog: AF0844
Description: Rabbit polyclonal antibody to Pim-1
Application: WB IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 50kDa; 36kD(Calculated).
Uniprot: P11309
RRID: AB_2834110

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%)
Clonality:
Polyclonal
Specificity:
Pim-1 Antibody detects endogenous levels of total Pim-1.
RRID:
AB_2834110
Cite Format: Affinity Biosciences Cat# AF0844, RRID:AB_2834110.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Oncogene PIM 1; Oncogene PIM1; PIM 1; pim 1 kinase 44 kDa isoform; Pim 1 kinase; pim 1 oncogene (proviral integration site 1); Pim 1 oncogene; PIM; PIM1; pim1 kinase 44 kDa isoform; PIM1_HUMAN; Pim2; PIM3; Proto oncogene serine/threonine protein kinase Pim 1; Proto-oncogene serine/threonine-protein kinase Pim-1; Proviral integration site 1; Proviral integration site 2;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P11309 PIM1_HUMAN:

Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines.

Description:
Pim1 a proto-oncogene serine/threonine kinase involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerced by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis.
Sequence:
MLLSKINSLAHLRAAPCNDLHATKLAPGKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Chicken
100
Rabbit
100
Zebrafish
75
Xenopus
63
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P11309 As Substrate

Site PTM Type Enzyme
K5 Ubiquitination
S8 Phosphorylation
T23 Phosphorylation
K24 Ubiquitination
K31 Ubiquitination
S46 Phosphorylation
K67 Ubiquitination
K94 Ubiquitination
S98 Phosphorylation
K169 Ubiquitination
K183 Ubiquitination
S189 Phosphorylation P11309 (PIM1)
K194 Ubiquitination
S261 Phosphorylation
S308 Phosphorylation

PTMs - P11309 As Enzyme

Substrate Site Source
O14757 (CHEK1) S280 Uniprot
O43524 (FOXO3) T32 Uniprot
O43524 (FOXO3) S253 Uniprot
P01106 (MYC) S329 Uniprot
P10275 (AR) S215 Uniprot
P10275 (AR) T851 Uniprot
P11309 (PIM1) S189 Uniprot
P27448-3 (MARK3) T90 Uniprot
P27448 (MARK3) T95 Uniprot
P27448-3 (MARK3) S96 Uniprot
P30304-1 (CDC25A) S116 Uniprot
P36888 (FLT3) Y591 Uniprot
P38936 (CDKN1A) T145 Uniprot
P38936 (CDKN1A) S146 Uniprot
P46527 (CDKN1B) T157 Uniprot
P46527 (CDKN1B) T198 Uniprot
P61073 (CXCR4) S339 Uniprot
P68431 (HIST1H3J) S11 Uniprot
Q00987 (MDM2) S166 Uniprot
Q00987 (MDM2) S186 Uniprot
Q01860 (POU5F1) S288 Uniprot
Q01860 (POU5F1) S289 Uniprot
Q04206 (RELA) S276 Uniprot
Q12778 (FOXO1) T24 Uniprot
Q12778 (FOXO1) S256 Uniprot
Q12778 (FOXO1) S319 Uniprot
Q13309 (SKP2) S64 Uniprot
Q13309 (SKP2) S72 Uniprot
Q13309 (SKP2) T417 Uniprot
Q13761 (RUNX3) S149 Uniprot
Q13761 (RUNX3) T151 Uniprot
Q13761 (RUNX3) T153 Uniprot
Q13761 (RUNX3) T155 Uniprot
Q8TA86 (RP9) S212 Uniprot
Q8TA86 (RP9) S214 Uniprot
Q92934 (BAD) S75 Uniprot
Q92934 (BAD) S99 Uniprot
Q92934 (BAD) S118 Uniprot
Q96B36 (AKT1S1) T246 Uniprot
Q99683 (MAP3K5) S83 Uniprot
Q99801 (NKX3-1) T89 Uniprot
Q99801 (NKX3-1) S185 Uniprot
Q99801 (NKX3-1) S186 Uniprot
Q99801 (NKX3-1) S195 Uniprot
Q99801 (NKX3-1) S196 Uniprot
Q9BZS1 (FOXP3) S422 Uniprot
Q9UNQ0 (ABCG2) T362 Uniprot

Research Backgrounds

Function:

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B, induces 14-3-3 proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis. Also phosphorylates and activates the ATP-binding cassette transporter ABCG2, allowing resistance to drugs through their excretion from cells.

PTMs:

Autophosphorylated on both serine/threonine and tyrosine residues. Phosphorylated. Interaction with PPP2CA promotes dephosphorylation.

Ubiquitinated, leading to proteasomal degradation.

Subcellular Location:

Cytoplasm. Nucleus.

Cell membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed primarily in cells of the hematopoietic and germline lineages. Isoform 1 and isoform 2 are both expressed in prostate cancer cell lines.

Subunit Structure:

Isoform 1 is isolated as a monomer whereas isoform 2 complexes with other proteins (By similarity). Binds to RP9 (By similarity). Isoform 2, but not isoform 1, binds BMX. Isoform 1 interacts with CDKN1B and FOXO3. Interacts with BAD (By similarity). Interacts with PPP2CA; this interaction promotes dephosphorylation of PIM1, ubiquitination and proteasomal degradation. Interacts with HSP90AA1, this interaction stabilizes PIM1 protein levels. Interacts (ubiquitinated form) with HSP70 and promotes its proteosomal degradation. Interacts with CDKN1A. Interacts with CDC25C. Interacts (via N-terminal 96 residues) with CDC25A (By similarity). Interacts with MAP3K5. Interacts with MYC (By similarity). Interacts with CBX3.

Family&Domains:

Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. PIM subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

References

1). The oncomicropeptide APPLE promotes hematopoietic malignancy by enhancing translation initiation. Molecular cell, 2022 (PubMed: 34555354) [IF=16.0]

Application: WB    Species: Human    Sample:

Figure 7APPLE supports a specific mRNA translation program and contributes to cancer progression

2). Dehydroepiandrosterone attenuates pulmonary artery and right ventricular remodeling in a rat model of pulmonary hypertension due to left heart failure. LIFE SCIENCES, 2019 (PubMed: 30605649) [IF=6.1]

Application: WB    Species: rat    Sample: lung

Fig. 6. |DHEA suppressed STAT3/NFAT signal pathway in lung. A, PY750-STAT3 and STAT3; B, NFATc2; C, Pim-1; D, Survivin. The top shows representative immunoblots, and the bottom shows the densitometric assessment. The values are means ± SE, n = 5 rats per group; *P < 0.05 versus the sham group, #P < 0.05 versus the PH-LHF group.

3). The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability. Chemical research in toxicology, 2024 (PubMed: 38815162) [IF=4.1]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.